tradingkey.logo
tradingkey.logo
Pesquisar

Guardant Health Inc

GH
Adicionar à lista de desejos
99.940USD
+3.230+3.34%
Fechamento 05/12, 16:00ETCotações atrasadas em 15 min
12.49BValor de mercado
PerdaP/L TTM

Mais detalhes de Guardant Health Inc Empresa

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Informações de Guardant Health Inc

Código da empresaGH
Nome da EmpresaGuardant Health Inc
Data de listagemOct 04, 2018
CEOTalasaz (Amirali)
Número de funcionários1999
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 04
Endereço3100 Hanover Street
CidadePALO ALTO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94304
Telefone18556988887
Sitehttps://guardanthealth.com/
Código da empresaGH
Data de listagemOct 04, 2018
CEOTalasaz (Amirali)

Executivos da empresa Guardant Health Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
79.91K
+73.68%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
65.95K
+13.72%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
46.56K
+10.63%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
--
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
18.32K
--
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
11.18K
--
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
8.53K
+1.57%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
79.91K
+73.68%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
65.95K
+13.72%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
46.56K
+10.63%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
24.31K
--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Oncology
683.60M
69.61%
Biopharma and data
210.13M
21.40%
Screening
79.73M
8.12%
Licensing and other
8.56M
0.87%
Por RegiãoUSD
Nome
Receita
Proporção
United States
923.28M
94.02%
International
58.74M
5.98%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Oncology
683.60M
69.61%
Biopharma and data
210.13M
21.40%
Screening
79.73M
8.12%
Licensing and other
8.56M
0.87%

Distribuição de ações

Atualizado em: seg, 11 de mai
Atualizado em: seg, 11 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
6.51%
Vanguard Portfolio Management, LLC
4.40%
Vanguard Capital Management, LLC
4.24%
T. Rowe Price Associates, Inc.
4.15%
Invesco Advisers, Inc.
3.75%
Outro
76.94%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
6.51%
Vanguard Portfolio Management, LLC
4.40%
Vanguard Capital Management, LLC
4.24%
T. Rowe Price Associates, Inc.
4.15%
Invesco Advisers, Inc.
3.75%
Outro
76.94%
Tipos de investidores
Investidores
Proporção
Investment Advisor
47.17%
Investment Advisor/Hedge Fund
31.01%
Hedge Fund
14.16%
Individual Investor
4.08%
Research Firm
3.11%
Sovereign Wealth Fund
1.74%
Bank and Trust
1.09%
Pension Fund
0.83%
Private Equity
0.12%

Participação acionária institucional

Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
894
134.76M
101.63%
-4.83M
2025Q4
825
125.59M
97.48%
-16.73M
2025Q3
765
128.93M
100.07%
-13.82M
2025Q2
759
134.16M
107.59%
-14.14M
2025Q1
783
130.34M
105.23%
-16.59M
2024Q4
746
130.16M
105.47%
-20.09M
2024Q3
780
137.29M
111.53%
-9.70M
2024Q2
801
127.50M
103.74%
-18.45M
2024Q1
826
124.00M
101.88%
-12.71M
2023Q4
856
120.18M
99.30%
-14.26M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
8.63M
6.58%
+59.33K
+0.69%
Dec 31, 2025
T. Rowe Price Associates, Inc.
5.51M
4.2%
+1.41M
+34.38%
Dec 31, 2025
Invesco Advisers, Inc.
4.98M
3.79%
+333.09K
+7.17%
Dec 31, 2025
Two Sigma Investments, LP
4.55M
3.47%
+638.07K
+16.29%
Dec 31, 2025
Baillie Gifford & Co.
4.89M
3.73%
-237.67K
-4.63%
Dec 31, 2025
Capital International Investors
3.53M
2.69%
-1.16M
-24.75%
Dec 31, 2025
Geode Capital Management, L.L.C.
3.21M
2.45%
+277.00K
+9.43%
Dec 31, 2025
Franklin Advisers, Inc.
2.94M
2.24%
+23.45K
+0.80%
Dec 31, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Franklin Genomic Advancements ETF
9.3%
Global X Genomics & Biotechnology ETF
7.01%
ARK Genomic Revolution ETF
5.81%
First Trust Nasdaq Lux Digi Health Solutions ETF
5.17%
Invesco Dorsey Wright Healthcare Momentum ETF
4.73%
ROBO Global Healthcare Technology & Innovation ETF
3.53%
State Street SPDR S&P Health Care Services ETF
3.35%
iShares Health Innovation Active ETF
3.27%
Simplify Health Care ETF
2.36%
Alpha Architect U.S. Quantitative Momentum ETF
2.35%
Ver Mais
Franklin Genomic Advancements ETF
Proporção9.3%
Global X Genomics & Biotechnology ETF
Proporção7.01%
ARK Genomic Revolution ETF
Proporção5.81%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção5.17%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção4.73%
ROBO Global Healthcare Technology & Innovation ETF
Proporção3.53%
State Street SPDR S&P Health Care Services ETF
Proporção3.35%
iShares Health Innovation Active ETF
Proporção3.27%
Simplify Health Care ETF
Proporção2.36%
Alpha Architect U.S. Quantitative Momentum ETF
Proporção2.35%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI